Leading Innovations in Hepatitis and Cytokines
English
手机端banner01
long-acting interferon drug product company in Hepatitis and Cytokines

Welcome To Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. is an innovative biopharmaceutical company and a listed company on the Science and Technology Innovation Board (SSE STAR Market) in China, specializing in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to becoming a leader in solving cytokine medicine-based systemic immune problems, providing better solutions for major diseases (such as viral hepatitis, malignant tumors) and immunotherapy. Looking into the future, Amoytop Biotech is especially focusing on CHB (chronic hepatitis B) treatment and will keep advancing the clinical research progress of multiple ongoing pipeline programs aiming to achieve breakthroughs in the clinical cure of CHB.

Research and Innovation

Amoytop Biotech is a leading biopharmaceutical company in China, specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
  • R&D Management
    According to company's development strategy, basing on the characteristics, life cycle management and trends...
  • R&D Team
    Insisting on constant innovation and development, Amoytop Biotech has created research...​​​​​​​
  • Pipelines
    Focusing on major disease treatment and aiming to provide better innovative protein drugs...
  • Innovation Achievements
    After over 20 years of innovation and development, Amoytop Biotech has owned many core technology platform...

Specialized In R&D And Production Of Recombinant Protein Products

Prodcut Center

Stay Updated With Our Latest News

20240327-165119_889_667_877_493.jpg
New LOGO Comes on Stage: Amoytop Biotech Improves Its Brand Image.

On January 17, Tebao Biotech held a brand image upgrade launch ceremony in Xiamen. The company's brand visual image was fully refreshed and upgraded, and a new brand LOGO and brand upgrade promotional video were released, marking the official launch of Tebao Biotech's new brand development strategy.

20240327-165323.jpg
Launch of New Product-Pegneugen (Telpegfilgrastim Injection)

Xiamen, China, July 1, 2023/--Xiamen Amoytop Biotech Co., Ltd. (referred to as Amoytop Biotech hereinafter) today announced that Pegneugen® (Telpegfilgrastim Injection) has been approved by National Medical Products Administration (NMPA) and is available for marketing.

Contact Details

Emal: international@amoytop.com; reagent@amoytop.com
Tel: +86-592-6889106
Hand phone: +86-18060918257
Fax: +86-592-6889110
Address: No. 330 Wengjiao Road, Xinyang Industry Zone of             Haicang, Xiamen, Fujian, P.R.China

Get In Touch

Get In Touch
Facebook
Twitter
LinkedIn
Instagram

WELCOME

Specialized in R&D and production of recombinant protein drugs, and committed to providing better solutions for viral hepatitis, malignant tumor and immunotherapy etc..
Copyright © 2023 Amoytop Biotech All Rights Reserved. Support by Leadong｜ Sitemap.  Privacy Policy​​​​​​​
Leave a Message
Get In Touch